Sarepta Therapeutics (SRPT) Price & Analysis

Compare

3,800 Followers

SRPT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$10.42 - $150.48

Previous CloseN/A

Volume185.86K

Average Volume (3M)11.30M

Market Cap

$1.27B

Enterprise Value$2.89B

Total Cash (Recent Filing)$522.76M

Total Debt (Recent Filing)$1.34B

Price to Earnings (P/E)19.6

Beta0.87

Next Earnings

Jul 30, 2025

EPS Estimate

0.78

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.60

Shares Outstanding98,277,030

10 Day Avg. Volume18,382,164

30 Day Avg. Volume11,299,733

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)1.58

Price to Sales (P/S)0.00

P/FCF Ratio-2.65

Enterprise Value/Market Cap2.29

Enterprise Value/Revenue0.40

Enterprise Value/Gross Profit1.60

Enterprise Value/Ebitda6.00

Forecast

1Y Price Target

$21.00

Price Target Upside63.04% Upside

Rating ConsensusHold

Number of Analyst Covering28

Sarepta Therapeutics News

See All News >

Bulls Say, Bears Say

Bulls Say

Ex-US SalesRoche reported an increase in ex-US Elevidys sales, showing some valuation upside to SRPT stock.

Market Re-entry ProbabilityThere is a 70-80% probability that ELEVIDYS returns to the market in the ambulatory setting following a safety review, with possible modifications to the label including additional screening and monitoring requirements.

Parental SupportParents are still supportive of ELEVIDYS, and there will be a significant push to get ambulatory use back by parents and advocacy groups.

Bears Say

FDA ChallengesThe path to resumption of Elevidys commercialization may be arduous due to additional clinical data requirements by the FDA.

Financial PressureWith $1.1B in outstanding convertible debt due in 2027 and cash totaling only $850M, the lack of an immediate-term revenue driver to fill the ELEVIDYS gap highlights the challenges that Sarepta will face to pay back its debt in two years, putting the company under significant financial pressure in the medium-term.

Safety ConcernsThree patient deaths related to acute hepatotoxicity following treatment have been reported, which might influence FDA's decisions.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

4.10% Insiders

29.18% Mutual Funds

1.09% Other Institutional Investors

43.84% Public Companies and Individual Investors

Detailed Ownership Overview >

SRPT FAQ

What was Sarepta Therapeutics’s price range in the past 12 months?

Sarepta Therapeutics lowest stock price was $10.41 and its highest was $150.48 in the past 12 months.

What is Sarepta Therapeutics’s market cap?

Sarepta Therapeutics’s market cap is $1.27B.

When is Sarepta Therapeutics’s upcoming earnings report date?

Sarepta Therapeutics’s upcoming earnings report date is Jul 30, 2025 which is in 4 days.

How were Sarepta Therapeutics’s earnings last quarter?

Sarepta Therapeutics released its earnings results on May 06, 2025. The company reported -$4.6 earnings per share for the quarter, missing the consensus estimate of -$3.207 by -$1.393.

Is Sarepta Therapeutics overvalued?

According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sarepta Therapeutics pay dividends?

Sarepta Therapeutics does not currently pay dividends.

What is Sarepta Therapeutics’s EPS estimate?

Sarepta Therapeutics’s EPS estimate is 0.78.

How many shares outstanding does Sarepta Therapeutics have?

Sarepta Therapeutics has 98,277,030 shares outstanding.

What happened to Sarepta Therapeutics’s price movement after its last earnings report?

Sarepta Therapeutics reported an EPS of -$4.6 in its last earnings report, missing expectations of -$3.207. Following the earnings report the stock price went down -21.455%.

Which hedge fund is a major shareholder of Sarepta Therapeutics?

Currently, no hedge funds are holding shares in SRPT

Sarepta Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-23.61%

Trailing 12-Months

Asset Growth

7.47%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sarepta Therapeutics

Sarepta Therapeutics, Inc. is a biotechnology company focused on the discovery and development of precision genetic medicines to treat rare diseases. The company is a leader in the research and development of RNA-based therapeutics, gene therapy, and other genetic medicine technologies. Its core products are primarily aimed at treating Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration and weakness. Sarepta's portfolio includes approved therapies, such as EXONDYS 51, VYONDYS 53, and AMONDYS 45, which are exon-skipping therapies addressing specific mutations in the DMD gene.

SRPT Company Deck

SRPT Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted significant revenue growth and strong demand projections for the future. However, challenges such as the tragic patient safety incident, administrative delays, and site capacity imbalances have led to a downward revision of revenue guidance. Despite these challenges, the company remains optimistic about long-term demand and continues to work on addressing the issues.Read More>

SRPT Stock 12 Month Forecast

Average Price Target

$21.00

▲(63.04%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","157":"$157","43.75":"$43.8","81.5":"$81.5","119.25":"$119.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,43.75,81.5,119.25,157],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.71,22.501538461538463,27.293076923076924,32.08461538461539,36.87615384615385,41.667692307692306,46.45923076923077,51.25076923076923,56.042307692307695,60.83384615384616,65.62538461538462,70.41692307692307,75.20846153846153,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.71,17.963076923076922,18.216153846153848,18.46923076923077,18.722307692307695,18.975384615384616,19.228461538461538,19.481538461538463,19.734615384615385,19.987692307692306,20.24076923076923,20.493846153846153,20.74692307692308,{"y":21,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.71,16.886153846153846,16.062307692307694,15.23846153846154,14.414615384615384,13.590769230769231,12.766923076923078,11.943076923076923,11.11923076923077,10.295384615384616,9.471538461538461,8.647692307692308,7.823846153846155,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":156.75,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":144.01,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.78,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.33,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.29,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.95,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.59,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.72,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.78,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.74,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 63, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >